Suppr超能文献

立体定向放射外科或笔形束质子治疗新诊断的斜坡脊索瘤后肿瘤控制情况的比较:一项单中心回顾性研究

Comparison of Tumor Control After Stereotactic Radiosurgery or Pencil Beam Proton Therapy for Newly Diagnosed Clival Chordomas: A Single-Center Retrospective Study.

作者信息

Hong Sukwoo, Mahajan Anita, Laack Nadia N, Link Michael J, Shinya Yuki, O'Brien Erin, Stokken Janalee K, Janus Jeffrey R, Choby Garret W, Van Gompel Jamie J

机构信息

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

World Neurosurg. 2023 Oct;178:e510-e519. doi: 10.1016/j.wneu.2023.07.109. Epub 2023 Aug 1.

Abstract

OBJECTIVE

To compare outcomes of proton radiation therapy (PRT), stereotactic radiosurgery (SRS), and x-ray-based radiation with an SRS boost (XRT + SRS) for newly diagnosed clival chordoma.

METHODS

Consecutive patients who underwent PRT or SRS in our facility were retrospectively reviewed.

RESULTS

A total of 59 patients were identified (PRT, 36; SRS, 11; XRT + SRS, 12). The mean age (± standard deviation) was 46 ± 20 years, with 54% being male. The mean tumor diameter (± standard deviation) was 3.7 ± 1.5 cm, and 21 (36%) involved the lower clivus. Gross total or near-total resection was attained in 27 patients (46%), all of whom received PRT. PRT was administered with a median prescribed dose of 70.8 Gy (range, 66.0-76.0). SRS involved a median marginal dose of 16 Gy (range, 14-20) and a median maximal dose of 36 Gy (range, 30-45). The XRT + SRS group was treated with an SRS marginal dose of 12.5 Gy (range, 10-20), a maximal dose of 27 Gy (range, 20-40), and an XRT prescription dose of 50.4 Gy (range, 45.0-59.4). Fifteen recurrences were observed (PRT, 6; SRS, 5; XRT + SRS, 4). For the entire cohort (n = 59), recurrence was associated with the degree of resection (P = 0.042), but not with radiation groups (P = 0.98). For patients after subtotal resection or biopsy (n = 32), the SRS ± XRT group was associated with few recurrences (hazard ratio, 0.260; 95% confidence interval, 0.069-0.98; P = 0.046).

CONCLUSIONS

Patients after subtotal resection or biopsy may benefit from the incorporation of SRS.

摘要

目的

比较质子放射治疗(PRT)、立体定向放射外科治疗(SRS)以及基于X线放射并联合SRS增敏(XRT + SRS)用于新诊断的斜坡脊索瘤的治疗效果。

方法

对在我院接受PRT或SRS治疗的连续性患者进行回顾性分析。

结果

共纳入59例患者(PRT组36例;SRS组11例;XRT + SRS组12例)。平均年龄(±标准差)为46±20岁,男性占54%。平均肿瘤直径(±标准差)为3.7±1.5 cm,21例(36%)累及斜坡下部。27例患者(46%)实现了大体全切或近全切,所有这些患者均接受了PRT治疗。PRT的中位处方剂量为70.8 Gy(范围66.0 - 76.0 Gy)。SRS的中位边缘剂量为16 Gy(范围14 - 20 Gy),中位最大剂量为36 Gy(范围30 - 45 Gy)。XRT + SRS组的SRS边缘剂量为12.5 Gy(范围10 - 20 Gy),最大剂量为27 Gy(范围20 - 40 Gy),XRT处方剂量为50.4 Gy(范围45.0 - 59.4 Gy)。观察到15例复发(PRT组6例;SRS组5例;XRT + SRS组4例)。对于整个队列(n = 59),复发与切除程度相关(P = 0.042),但与放疗组无关(P = 0.98)。对于次全切除或活检后的患者(n = 32),SRS±XRT组复发较少(风险比,0.260;95%置信区间,0.069 - 0.98;P = 0.046)。

结论

次全切除或活检后的患者可能从联合SRS治疗中获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验